Verve Therapeutics, Inc.
VERVNASDAQHealthcare
$11.13
+$0.03(+0.27%)
Market Cap$994044786
P/E Ratio—
52W High$11.405
52W Low$2.865
Verve Therapeutics, Inc. (VERV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VERV · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 14, 2025EPS Actual
-$0.59
Est. -$0.70 · +15.7%
Revenue
—
Est. $0.00B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 14, 2025
After Market Close
▲ Beat EPS🔥 9-Quarter EPS Beat Streak
VERV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.70 | -$0.59 | +15.7% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.71 | -$0.35 | +50.7% | $0.03B | $0.01B | +266.1% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.72 | -$0.58 | +19.4% | $0.01B | $0.00B | +232.4% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$0.70 | -$0.59 | +15.7% | $0.01B | $0.00B | +150.0% |
| ▲ Q3 FY2024 | Aug 8, 2024 | -$0.68 | -$0.59 | +13.2% | $0.01B | $0.00B | +178.7% |
| ▲ Q2 FY2024 | May 8, 2024 | -$0.68 | -$0.59 | +13.2% | $0.01B | $0.00B | +170.1% |
| ▲ Q1 FY2024 | Feb 27, 2024 | -$0.80 | -$0.69 | +13.8% | $0.01B | $0.00B | +36.6% |
| ▲ Q4 FY2023 | Nov 7, 2023 | -$0.91 | -$0.72 | +20.9% | $0.00B | $0.00B | +223.4% |
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.59
EPS Est.
-$0.70
EPS Surpr.
+15.7%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.35
EPS Est.
-$0.71
EPS Surpr.
+50.7%
Revenue
$0.03B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.58
EPS Est.
-$0.72
EPS Surpr.
+19.4%
Revenue
$0.01B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.59
EPS Est.
-$0.70
EPS Surpr.
+15.7%
Revenue
$0.01B
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.59
EPS Est.
-$0.68
EPS Surpr.
+13.2%
Revenue
$0.01B
Q2 FY2024
May 8, 2024Beat
EPS Actual
-$0.59
EPS Est.
-$0.68
EPS Surpr.
+13.2%
Revenue
$0.01B
Q1 FY2024
Feb 27, 2024Beat
EPS Actual
-$0.69
EPS Est.
-$0.80
EPS Surpr.
+13.8%
Revenue
$0.01B
Q4 FY2023
Nov 7, 2023Beat
EPS Actual
-$0.72
EPS Est.
-$0.91
EPS Surpr.
+20.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.70 | $-0.70 | $-0.70 | 1 |
| Q3 FY2026 | $-0.69 | $-0.69 | $-0.69 | 1 |
| Q2 FY2026 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Q1 FY2026 | $-0.68 | $-0.68 | $-0.68 | 1 |
| Q4 FY2025 | $-0.75 | $-0.75 | $-0.75 | 2 |
| Q3 FY2025 | $-0.88 | $-0.73 | $-0.60 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 14, 2025 | +15.7% | $11.13 | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | +50.7% | $4.16 | $4.31 | +3.61% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +19.4% | $6.31 | $6.20 | -1.74% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +15.7% | $6.05 | $6.38 | +5.45% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +13.2% | $5.68 | $5.44 | -4.23% |
| ▲ Q2 FY2024 | May 8, 2024 | +13.2% | $6.16 | $6.08 | -1.30% |
| ▲ Q1 FY2024 | Feb 27, 2024 | +13.8% | $14.44 | $17.54 | +21.47% |
| ▲ Q4 FY2023 | Nov 7, 2023 | +20.9% | $14.98 | $18.70 | +24.83% |
Q3 FY2025—
Report Date
Aug 14, 2025
EPS Beat/Miss
+15.7%
Price Before
$11.13
Price After
—
Q2 FY2025+3.61%
Report Date
May 14, 2025
EPS Beat/Miss
+50.7%
Price Before
$4.16
Price After
$4.31
Q1 FY2025-1.74%
Report Date
Feb 27, 2025
EPS Beat/Miss
+19.4%
Price Before
$6.31
Price After
$6.20
Q4 FY2024+5.45%
Report Date
Nov 5, 2024
EPS Beat/Miss
+15.7%
Price Before
$6.05
Price After
$6.38
Q3 FY2024-4.23%
Report Date
Aug 8, 2024
EPS Beat/Miss
+13.2%
Price Before
$5.68
Price After
$5.44
Q2 FY2024-1.30%
Report Date
May 8, 2024
EPS Beat/Miss
+13.2%
Price Before
$6.16
Price After
$6.08
Q1 FY2024+21.47%
Report Date
Feb 27, 2024
EPS Beat/Miss
+13.8%
Price Before
$14.44
Price After
$17.54
Q4 FY2023+24.83%
Report Date
Nov 7, 2023
EPS Beat/Miss
+20.9%
Price Before
$14.98
Price After
$18.70
Avg Beat Reaction+6.87%
Beat Rate8 / 8 quarters
Largest Move+24.83% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VERV ends December
Verve Therapeutics, Inc. (VERV) most recently reported earnings on August 14, 2025 for Q3 FY2025, posting EPS of $-0.59 — beating the analyst consensus of $-0.70 by +15.7%. VERV has beaten EPS estimates for 9 consecutive quarters. The next VERV earnings date is expected around September 1, 2026.
Each quarter, investors track VERV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VERV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VERV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VERV earnings · 5 questionsVerve Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. VERV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VERV historically reports after market close (AMC).
VERV earnings datewhen is VERV earningsVERV next earnings datewhen does VERV report earningsVERV earnings calendar
▸ Source: FMP · Verve Therapeutics, Inc. SEC filings · US GAAP · Verve Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026